# A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Source: https://onco.cc/trials/nct06689163/  
OnCo record `nct06689163` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Prednisone in prostate cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone is a phase 1/2 interventional study registered as NCT06689163 by Jiangsu HengRui Medicine Co., Ltd., with 66 participants planned, started 2024-12-11 and due to reach its primary completion in 2025-11-30. Interventions recorded: HRS-1167 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06689163
- Phase: 1/2
- Setting: An Open, Multicenter Phase Ib/II Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT06689163: https://clinicaltrials.gov/study/NCT06689163

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06689163.json